Privately-held Redwood City, California-based firm announces a Japanese 50/50 joint venture with Nichiban Co., Ltd. to develop and manufacture transdermal drug delivery systems for pharmaceutical firms in that country. Nichiban markets bandages and surgical tapes and has developed an adrenocortical steroid tape (Tokuderm) and a nitroglycerin transdermal patch (Herzer or Millisrol Tape). The new venture Nichiban DDS K.K. will be headquartered in Osaka.
You may also be interested in...
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.